Universal peptide vaccines - Optimal peptide vaccine design based on viral sequence conservation

Vaccine

Volumn 29, Issue 47, 2011, Pages 8745-8753

  Toussaint, Nora C ^a   Maman, Yaakov ^b   Kohlbacher, Oliver ^a   Louzoun, Yoram ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b BAR ILAN UNIVERSITY   (Israel)

Author keywords

Bioinformatics; CTL; Epitope; MHC; Vaccine

Indexed keywords

EPITOPE; PEPTIDE VACCINE; VIRUS PROTEIN;

ARTICLE; CYTOLYSIS; DRUG DESIGN; FEASIBILITY STUDY; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; INFLUENZA VIRUS; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS STRAIN;

EPITOPES; HEPACIVIRUS; HIV; HUMANS; MODELS, THEORETICAL; ORTHOMYXOVIRIDAE; VACCINES, SUBUNIT; VIRAL VACCINES;

EID: 82255174297     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.132     Document Type: Article

References (59)

1. Grebely J., Thomas D.L., Dore G.J. HCV reinfection studies and the door to vaccine development. J Hepatol 2009, 51(4):628-631.
2. Jin D.Y. Molecular pathogenesis of hepatitis C virus-associated hepatocellular carcinoma. Front Biosci 2007, 12:222-233.
3. Russell N.D., Graham B.S., Keefer M.C., McElrath M.J., Self S.G., Weinhold K.J., et al. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr 2007, 44(2):203-212.
4. Purcell A.W., McCluskey J., Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 2007, 6(5):404-414.
5. Bowen D.G., Walker C.M. Mutational escape from CD8(+) T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med 2005, 201(11):1709-1714.
6. Liu Y., McNevin J., Zhao H., Tebit D.M., Troyer R.M., McSweyn M., et al. Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-balanced escape. J Virol 2007, 81(22):12179-12188.
7. Peut V., Kent S.J. Fitness constraints on immune escape from HIV: implications of envelope as a target for both HIV-specific T cells and antibody. Curr HIV Res 2006, 4(2):191-197.
8. Uebelhoer L., Han J.H., Callendret B., Mateu G., Shoukry N.H., Hanson H.L., et al. Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness. PLoS Pathog 2008, 4(9):e1000143.
9. Vider-Shalit T., Almani M., Sarid R., Louzoun Y. The HIV hide and seek game: an immunogenomic analysis of the HIV epitope repertoire. AIDS 2009, 23(11):1311-1318.
10. Vider-Shalit T., Fishbain V., Raffaeli S., Louzoun Y. Phase-dependent immune evasion of herpesviruses. J Virol 2007, 81(17):9536-9545.
11. Vider-Shalit T., Sarid R., Maman K., Tsaban L., Levi R., Louzoun Y. Viruses selectively mutate their CD8+ T-cell epitopes - a large-scale immunomic analysis. Bioinformatics 2009, 25(12):i39-i44.
12. De Groot A.S., Marcon L., Bishop E.A., Rivera D., Kutzler M., Weiner D.B., et al. HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine 2005, 23(17-18):2136-2148.
13. Toussaint N.C., Dönnes P., Kohlbacher O. A mathematical framework for the selection of an optimal set of peptides for epitope-based vaccines. PLoS Comput Biol 2008, 4(12):e1000246.
14. Vider-Shalit T., Raffaeli S., Louzoun Y. Virus-epitope vaccine design: informatic matching the HLA-I polymorphism to the virus genome. Mol Immunol 2007, 44(6):1253-1261.
15. Kong W.P., Wu L., Wallstrom T.C., Fischer W., Yang Z.Y., Ko S.Y., et al. Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol 2009, 83(5):2201-2215.
16. Santra S., Liao H.X., Zhang R., Muldoon M., Watson S., Fischer W., et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 2010, 16(3):324-328.
17. Kiepiela P., Leslie A.J., Honeyborne I., Ramduth D., Thobakgale C., Chetty S., et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004, 432(7018):769-775.
18. Fischer W., Perkins S., Theiler J., Bhattacharya T., Yusim K., Funkhouser R., et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 2007, 13(1):100-106.
19. Barouch D.H., O'Brien K.L., Simmons N.L., King S.L., Abbink P., Maxfield L.F., et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010, 16(3):319-323.
20. Nowak M.A., Anderson R.M., McLean A.R., Wolfs T.F., Goudsmit J., May R.M. Antigenic diversity thresholds and the development of AIDS. Science 1991, 254(5034):963-969.
21. Fryer H.R., Frater J., Duda A., Roberts M.G., Phillips R.E., McLean A.R. Modelling the evolution and spread of HIV immune escape mutants. PLoS Pathog 2010, 6(11):e1001196.
22. De Re V., Simula M.P., Cannizzaro R., Sansonno D., Canzonieri V., Gloghini A., et al. HCV inhibits antigen processing and presentation and induces oxidative stress response in gastric mucosa. Proteomics Clin Appl 2008, 2(9):1290-1299.
23. Zimmermann M., Flechsig C., La Monica N., Tripodi M., Adler G., Dikopoulos N. Hepatitis C virus core protein impairs in vitro priming of specific T cell responses by dendritic cells and hepatocytes. J Hepatol 2008, 48(1):51-60.
24. Khu Y.L., Tan Y.J., Lim S.G., Hong W., Goh P.Y. Hepatitis C virus non-structural protein NS3 interacts with LMP7, a component of the immunoproteasome, and affects its proteasome activity. Biochem J 2004, 384(Pt 2):401-409.
25. Edgar R.C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 2004, 32(5):1792-1797.
26. Robinson J., Waller M.J., Fail S.C., McWilliam H., Lopez R., Parham P., et al. The IMGT/HLA database. Nucleic Acids Res 2009, 37:D1013-D1017.
27. Robinson J., Malik A., Parham P., Bodmer J.G., Marsh S.G. IMGT/HLA database - a sequence database for the human major histocompatibility complex. Tissue Antigens 2000, 55(3):280-287.
28. Parker K.C., Bednarek M.A., Coligan J.E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994, 152(1):163-175.
29. Meyer D., Singe R., Mack S., Lancaster A., Nelson M., Erlich H., et al. Single locus polymorphism of classical HLA genes. Immunobiology of the human MHC: proceedings of the 13th international histocompatibility workshop and conference 2007, 653-704. IHWG Press, Seattle. J. Hansen (Ed.).
30. Ginodi I., Vider-Shalit T., Tsaban L., Louzoun Y. Precise score for the prediction of peptides cleaved by the proteasome. Bioinformatics 2008, 24(4):477-483.
31. Toussaint N.C., Kohlbacher O. Towards in silico design of epitope-based vaccines. Expert Opin Drug Discov 2009, 4(10):1047-1060.
32. Sette A., Vitiello A., Reherman B., Fowler P., Nayersina R., Kast W.M., et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994, 153(12):5586-5592.
33. Pataki G. Teaching integer programming formulations using the traveling salesman problem. Siam Rev 2003, 45(1):116-123.
34. Zhang M., Gaschen B., Blay W., Foley B., Haigwood N., Kuiken C., et al. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 2004, 14(12):1229-1246.
35. Air G.M., Laver W.G. The neuraminidase of influenza virus. Proteins 1989, 6(4):341-356.
36. Gulati U., Hwang C.C., Venkatramani L., Gulati S., Stray S.J., Lee J.T., et al. Antibody epitopes on the neuraminidase of a recent H3N2 influenza virus (A/Memphis/31/98). J Virol 2002, 76(23):12274-12280.
37. Liu M., Chen H., Luo F., Li P., Pan Q., Xia B., et al. Deletion of N-glycosylation sites of hepatitis C virus envelope protein E1 enhances specific cellular and humoral immune responses. Vaccine 2007, 25(36):6572-6580.
38. Wu G., Yan S.M. Mutation trend of hemagglutinin of influenza A virus: a review from a computational mutation viewpoint. Acta Pharmacol Sin 2006, 27(5):513-526.
39. Cox R.J., Brokstad K.A., Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004, 59(1):1-15.
40. Fournillier A., Wychowski C., Boucreux D., Baumert T.F., Meunier J.C., Jacobs D., et al. Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites. J Virol 2001, 75(24):12088-12097.
41. Hindiyeh M., Ram D., Mandelboim M., Meningher T., Hirsh S., Robinov J., et al. Rapid detection of influenza A pandemic (H1N1) 2009 virus neuraminidase resistance mutation H275Y by real-time reverse transcriptase PCR. J Clin Microbiol 2010, 48(5):1884-1887.
42. Liu H., Yao X., Wang C., Han J. In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase. Mol Pharm 2010, 7(3):894-904.
43. Berkhoff E.G., Geelhoed-Mieras M.M., Jonges M., Smith D.J., Fouchier R.A., Osterhaus A.D., et al. An amino acid substitution in the influenza A virus hemagglutinin associated with escape from recognition by human virus-specific CD4+ T-cells. Virus Res 2007, 126(1-2):282-287.
44. Prosch S., Heider H., Schroeder C., Kruger D.H. Mutations in the hemagglutinin gene associated with influenza virus resistance to norakin. Arch Virol 1988, 102:125-129. (1-2).
45. Welbourn S., Pause A. The hepatitis C virus NS2/3 protease. Curr Issues Mol Biol 2007, 9(1):63-69.
46. Franck N., Le Seyec J., Guguen-Guillouzo C., Erdtmann L. Hepatitis C virus NS2 protein is phosphorylated by the protein kinase CK2 and targeted for degradation to the proteasome. J Virol 2005, 79(5):2700-2708.
47. Rao X., Costa A.I., van Baarle D., Kesmir C. A comparative study of HLA binding affinity and ligand diversity: implications for generating immunodominant CD8+ T cell responses. J Immunol 2009, 182(3):1526-1532.
48. Bihl F., Frahm N., Di Giammarino L., Sidney J., John M., Yusim K., et al. Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol 2006, 176(7):4094-4101.
49. Vider-Shalit T., Almani M., Sarid R., Louzoun Y. The HIV hide and seek game: an immunogenomic analysis of the HIV epitope repertoire. AIDS 2009, 23(11):1311-1318.
50. Jacks T., Power M.D., Masiarz F.R., Luciw P.A., Barr P.J., Varmus H.E. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 1988, 331(6153):280-283.
51. Wilson W., Braddock M., Adams S.E., Rathjen P.D., Kingsman S.M., Kingsman A.J. HIV expression strategies: ribosomal frameshifting is directed by a short sequence in both mammalian and yeast systems. Cell 1988, 55(6):1159-1169.
52. Addo M.M., Yu X.G., Rosenberg E.S., Walker B.D., Altfeld M. Cytotoxic T-lymphocyte (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection. DNA Cell Biol 2002, 21(9):671-678.
53. Kadolsky U.D., Asquith B. Quantifying the impact of human immunodeficiency virus-1 escape from cytotoxic T-lymphocytes. PLoS Comput Biol 2010, 6(11):e1000981.
54. Delport W., Scheffler K., Seoighe C. Frequent toggling between alternative amino acids is driven by selection in HIV-1. PLoS Pathog 2008, 4(12):e1000242.
55. Dakappagari N.K., Sundaram R., Rawale S., Liner A., Galloway D.R., Kaumaya P.T. Intracellular delivery of a novel multiepitope peptide vaccine by an amphipathic peptide carrier enhances cytotoxic T-cell responses in HLA-A*201 mice. J Pept Res 2005, 65(2):189-199.
56. Chianese-Bullock K.A., Irvin W.P., Petroni G.R., Murphy C., Smolkin M., Olson W.C., et al. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J Immunother 2008, 31(4):420-430.
57. Kenter G.G., Welters M.J.P., Valentijn A.R.P.M., Lowik M.J.G., van der Meer D.M.A.B., Vloon A.P.G., et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008, 14(1):169-177.
58. Slingluff C.L., Petroni G.R., Chianese-Bullock K.A., Smolkin M.E., Hibbitts S., Murphy C., et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 2007, 13(21):6386-6395.
59. Klade C.S., Wedemeyer H., Berg T., Hinrichsen H., Cholewinska G., Zeuzem S., et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 2008, 134(5):1385-1395.